240 likes | 388 Views
Cytokine and Soluble Fas Ligand Response in Children with Septic Acute Renal Failure (ARF) on CVVH. Paden ML, Fortenberry JD, Rigby MR, Trexler AM, Heard ML, Rogers K Children’s Healthcare of Atlanta at Egleston Division of Pediatric Critical Care Medicine
E N D
Cytokine and Soluble Fas Ligand Response in Children with Septic Acute Renal Failure (ARF) on CVVH Paden ML, Fortenberry JD,Rigby MR, Trexler AM, Heard ML, Rogers K Children’s Healthcare of Atlanta at Egleston Division of Pediatric Critical Care Medicine Emory University School of Medicine, Atlanta, GA USA
Sepsis and CRRT • In septic adults, CRRT • Improves hemodynamics (Kamijo Y. Intensive Care Med 2000;26(9):1355-9) • Allows control of fluid balance • Maximizes nutrition • Improves survival with high flow ultrafiltration rate (Ronco C, Lancet 2000;356:26-30) • Cytokine removal postulated as the basis for these effects (Bellomo R, Contrib Nephrol 2001;132:367-74)
Sepsis and CRRT:Peak Concentration Hypothesis Adapted from Ronco C, et al, Artif Organs 2003
Controversy in Sepsis and CRRT • Previous adult studies question the ability for CRRT to lower cytokine levels • Concentration ≠ activity • Cytokine clearance in children has not been adequately studied
Fas/Soluble Fas Ligand (sFasL) System • Apoptotic pathway in multiple tissues • Fas in HUS induced renal failure (Masri C, et al. Am J Kidney Dis 2000;36(4):859-62.) • Levels correlate with: • Development of oligoanuria • Need for acute dialysis • Decreased GFR at 1 year after injury • sFasL in ARDS (Imay Y, et al. JAMA 2003;289(16):2104-12.) • Significant correlation between changes in sFasL and changes in creatinine.
Hypothesis • Convective clearance of IL-6, IL-8, IL-10, and sFasL occurs in pediatric patients with acute renal failure (ARF) treated with CVVH.
Study Design • Enrollment of all patients on CVVH: • Acute renal failure • Greater than 5 kg • < 18 years old • Technique • CVVH via Braun Diapact • Citrate anticoagulation • Ultrafiltration rate 35-45 cc/kg/hour • Cytokines measured by cytometric bead array from BD Pharmagen • Serial measurements of cytokines • Pre-CVVH • 12, 24, 48 hours on CVVH • End of CVVH and 24 hours after
Study Design • Bacterial septic shock defined as • Vasopressor dependent • Positive blood culture • Compared values in children with bacterial septic shock/ARF to non-septic ARF patients
Results • Septic Shock Patients
Results • Non-septic ARF Patients
Results 24 Hours off CVVH End of CVVH 24 Hours 12 Hours 48 Hours Pre-CVVH
Results 24 Hours off CVVH End of CVVH 12 Hours 24 Hours Pre-CVVH 48 Hours
Absolute cytokine changes in septic shock/ARF patients * * p=0.04 p<0.02 Log Concentration (pg/ml)
Absolute cytokine changes in septic shock/ARF patients p=0.132 p=0.818 Log Concentration (pg/ml)
IL-8 Percent Changes From Pre-CVVH Baseline * * * * *p<0.03 * Non-septic ARF Patients Septic ARF Patients
Mean Percent Decrease in Septic Shock/ARF Patients *p<0.05 * * Non-septic ARF Patients Septic ARF Patients
Mean Percent Decrease in Septic Shock/ARF Patients *p<0.05 * * Non-septic ARF Patients Septic ARF Patients
Ultrafiltrate Cytokine Levels Non-septic ARF Patients Septic ARF Patients
Ultrafiltrate Cytokine Levels Non-septic ARF Patients Septic ARF Patients
sFasL Analysis 24 h off CVVH End of CVVH 12 h 48 h 24 h
sFasL Response • sFasL concentration pre-CVVH was similar in Septic Shock/ARF and non-septic ARF patients • Median 130 pg/ml (24-439) • Levels did not significantly decrease with CVVH (p=0.818)
Conclusions • CVVH significantly removes both pro-inflammatory (IL-6, IL-8) and anti-inflammatory (IL-10) cytokines in pediatric septic shock/ARF vs. non-septic patients • Absolute decrease • Greater relative decrease in septic patients compared to non-septic ARF patients • Convective clearance is likely mechanism • sFasL concentration is not changed by CVVH
Implications • Effects of decreasing cytokines remain uncertain • Future studies to evaluate cytokine clearance • “Regular” CVVH • High Volume Hemofiltration • Different filters • Clinical outcome studies